Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性（CHC）者接受α干扰素包括派罗欣治疗时存在功能失偿和死亡风险。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛素抵抗和糖尿病是慢性炎（CHC）中纤维化进展以及对抗病毒治疗无应答的危险因素。